Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2025)
Historic Current Deferred Revenue for Ginkgo Bioworks Holdings (DNA) over the last 7 years, with Q3 2025 value amounting to $25.2 million.
- Ginkgo Bioworks Holdings' Current Deferred Revenue rose 1022.98% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 1022.98%. This contributed to the annual value of $126.5 million for FY2024, which is 3753.09% down from last year.
- As of Q3 2025, Ginkgo Bioworks Holdings' Current Deferred Revenue stood at $25.2 million, which was up 1022.98% from $28.3 million recorded in Q2 2025.
- In the past 5 years, Ginkgo Bioworks Holdings' Current Deferred Revenue ranged from a high of $222.6 million in Q4 2022 and a low of $22.9 million during Q3 2024
- Its 5-year average for Current Deferred Revenue is $99.5 million, with a median of $126.5 million in 2024.
- In the last 5 years, Ginkgo Bioworks Holdings' Current Deferred Revenue surged by 9450000.0% in 2021 and then crashed by 8055.97% in 2024.
- Over the past 5 years, Ginkgo Bioworks Holdings' Current Deferred Revenue (Quarter) stood at $189.2 million in 2021, then rose by 17.65% to $222.6 million in 2022, then decreased by 9.03% to $202.5 million in 2023, then plummeted by 37.53% to $126.5 million in 2024, then crashed by 80.05% to $25.2 million in 2025.
- Its Current Deferred Revenue stands at $25.2 million for Q3 2025, versus $28.3 million for Q2 2025 and $33.7 million for Q1 2025.